Jan Storek

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Comparison of two flow cytometric methods enumerating CD4 T cells and CD8 T cells
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle 98104 2092, USA
    Cytometry 33:76-82. 1998
  2. ncbi request reprint Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 33:337-46. 2004
  3. pmc Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Clin Immunol 113:285-98. 2004
  4. ncbi request reprint Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 101:4209-18. 2003
  5. ncbi request reprint Factors affecting antibody levels after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:3319-24. 2003
  6. ncbi request reprint Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Transplantation 73:1154-8. 2002
  7. ncbi request reprint Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 9:781-4. 2003
  8. ncbi request reprint Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 96:3290-3. 2000
  9. ncbi request reprint Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 98:3505-12. 2001
  10. ncbi request reprint Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 97:3380-9. 2001

Detail Information

Publications36

  1. ncbi request reprint Comparison of two flow cytometric methods enumerating CD4 T cells and CD8 T cells
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle 98104 2092, USA
    Cytometry 33:76-82. 1998
    ..We conclude that the 2-color method is suitable for the enumeration of CD4+ T cells and CD8high T cells and reserves the third color for further enumeration of CD4+ or CD8high T cell subsets...
  2. ncbi request reprint Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 33:337-46. 2004
    ..In contrast, neither recipient immunization on days -1 and 50 nor donor immunization on day -20 appears to be efficacious for polysaccharide antigens and poorly immunogenic protein neo-antigens...
  3. pmc Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Clin Immunol 113:285-98. 2004
    ..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells...
  4. ncbi request reprint Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 101:4209-18. 2003
    ..No animals developed lymphoma. Bone density was not decreased. In conclusion, IL-7 raises CD4 T-cell counts in irradiated primates. It remains to be determined whether this is associated with clinical benefit...
  5. ncbi request reprint Factors affecting antibody levels after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:3319-24. 2003
    ....
  6. ncbi request reprint Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Transplantation 73:1154-8. 2002
    ..without irradiation), acute graft-versus-host disease (aGVHD), or chronic graft-versus-host disease (cGVHD) in multivariate analysis. We conclude that patient age is the primary determinant of CD4 T-lymphopoiesis after allogeneic HCT...
  7. ncbi request reprint Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 9:781-4. 2003
    ..63; P <.001), and day 180 (R = 0.66; P <.001) after transplantation. These results suggest that in the first 6 months after transplantation, most naive CD4 T cells are derived from the naive T cells infused with the graft...
  8. ncbi request reprint Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 96:3290-3. 2000
    ..009). CD28(-) CD8 T-cell counts showed no correlation with infection rates. In conclusion, the susceptibility of patients to infections late posttransplant may be due in part to the slow reconstitution of B cells and monocytes...
  9. ncbi request reprint Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 98:3505-12. 2001
    ..Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible...
  10. ncbi request reprint Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 97:3380-9. 2001
    ..008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)..
  11. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
    ..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study...
  12. ncbi request reprint Interleukin-7 improves reconstitution of antiviral CD4 T cells
    Hailing Lu
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Clin Immunol 114:30-41. 2005
    ..In conclusion, IL7 stimulates the expansion of CD4 T cells, including functional antiviral cells. Clinical risk-benefit ratio needs to be evaluated...
  13. pmc Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial
    Hirohisa Nakamae
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 16:384-94. 2010
    ....
  14. ncbi request reprint De novo generation of CD4 T cells against viruses present in the host during immune reconstitution
    Tomas Kalina
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA
    Blood 105:2410-4. 2005
    ..This finding provides a strong rationale to improve thymopoiesis in recipients of hematopoietic cell transplants and, perhaps, in other persons lacking de novo-generated CD4 T cells, such as AIDS patients and elderly persons...
  15. ncbi request reprint Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning
    Michael Maris
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Exp Hematol 31:941-52. 2003
    ..We studied immune reconstitution in 51 recipients of HLA-identical hematopoietic cellular transplant (HCT) after nonmyeloablative conditioning compared to a reference group of 67 recipients after myeloablative conditioning...
  16. pmc Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 14:1373-9. 2008
    ..Thus, the therapy may not be completely T cell lymphoablative...
  17. ncbi request reprint Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning
    Frederic Baron
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 6072, USA
    Biol Blood Marrow Transplant 12:1176-87. 2006
    ..Other factors significantly associated with delayed immune recovery were advanced donor age, low numbers of CD34 and T cells in the graft, and development of graft-versus-host disease...
  18. pmc Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial
    Brian Kornblit
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1340-7. 2013
    ..0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor engraftment early after transplantation...
  19. ncbi request reprint Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts
    Jan Storek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Immunol 102:249-57. 2002
    ..4% total body B cells. By inference, an average-size person may carry a total of approximately 4.1 x 10(11) CD4 T cells, > or = 4.5 x 10(11) CD8 T cells, and approximately 1.0 x 10(11) B cells...
  20. pmc Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation
    Abraham Guerrero
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 18:66-75. 2012
    ..These differences may be because of a transient delay in CMV-specific immune reconstitution following PBSC transplantation...
  21. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  22. ncbi request reprint Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning
    Julia C Morris
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98105, USA
    Blood 103:492-9. 2004
    ..In summary, we report the induction of transgene-specific immune responses after transplantation of lentivirally transduced repopulating cells in a myeloablative setting...
  23. ncbi request reprint Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
    Morgan Hakki
    Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle, USA
    Blood 102:3060-7. 2003
    ..Subclinical CMV reactivation while on ganciclovir appears to be a potent stimulator of T-cell function. These findings have implications for vaccination and adoptive-immunotherapy strategies in this population...
  24. pmc An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients
    Margaret Pollack
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 17:664-73. 2011
    ..Center size and age of primary patient population were not associated with many reported differences in strategies...
  25. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
    ..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...
  26. doi request reprint Long-term response of juvenile idiopathic arthritis after conditioning with 8 Gy total body irradiation followed by autologous peripheral blood stem cells: case report
    Ann Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Pediatr Transplant 14:E65-9. 2010
    ..This regimen should be considered for patients with JIA refractory to medical therapies, including previous low intensity regimen HCT...
  27. doi request reprint Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease
    James A Russell
    Alberta Blood and Marrow Transplant Program, Department of Medicine, Foothills Hospital, Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Biol Blood Marrow Transplant 14:888-95. 2008
    ..Older HR patients experience more GVHD and more GVHD-related death than others, but NRM is no higher than reported with many nonmyeloablative regimens...
  28. ncbi request reprint Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft
    Jan Storek
    University of Calgary, 3330 Hospital Drive NW, HSC1869, Calgary, T2N 4N1, Canada
    Expert Opin Biol Ther 8:583-97. 2008
    ..After hematopoietic cell transplantation (HCT), there is a prolonged period of immune deficiency...
  29. doi request reprint High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
    Michelle Geddes
    Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    Biol Blood Marrow Transplant 14:220-8. 2008
    ..min. These data support a role for therapeutic dose monitoring and dose adjustment with daily i.v. busulfan...
  30. ncbi request reprint Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin
    James A Russell
    Alberta Blood and Bone Marrow Transplant Program, Department of Oncology, Foothills Hospital, Alberta, Canada
    Biol Blood Marrow Transplant 13:814-21. 2007
    ..04), respectively. This combination appears relatively well tolerated, gives equivalent final outcomes from MRD and AD, and may be a reasonable alternative to conventional myeloablative regimens...
  31. ncbi request reprint Immune reconstitution following hematopoietic stem-cell transplantation
    Michelle Geddes
    Division of Hematology and Hematologic Malignancies, University of Calgary, Canada
    Best Pract Res Clin Haematol 20:329-48. 2007
    ..Therapies to improve immune function include vaccinations, immunoglobulins for recurrent infections, cytokines, and antigen-specific donor lymphocyte infusions...
  32. ncbi request reprint Transgene expression by a large fraction of dendritic cells following autologous transplantation of retrovirally transduced CD34 cells
    Jan Storek
    Stem Cells Dev 15:619-21. 2006
  33. pmc High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
    Peter A McSweeney
    University of Colorado Health Sciences Center, Denver 80262, USA
    Blood 100:1602-10. 2002
    ..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies...
  34. ncbi request reprint Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis
    Jan Storek
    Clin Immunol 121:118-9. 2006
  35. ncbi request reprint Measles in bone marrow transplant recipients
    Jan Storek
    Blood 99:3070. 2002
  36. ncbi request reprint Low T cell receptor excision circle levels in patients thymectomized 25-54 years ago
    Jan Storek
    Immunol Lett 89:91-2. 2003

Research Grants8

  1. T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
    Jan Storek; Fiscal Year: 1999
    ..This will give impetus for developing strategies to enable older patients to generate T cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or thymus grafting. ..
  2. T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
    Jan Storek; Fiscal Year: 2000
    ..This will give impetus for developing strategies to enable older patients to generate T cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or thymus grafting. ..
  3. Preclinical Testing of Interleukin-7 in Primates
    Jan Storek; Fiscal Year: 2001
    ..These results will be used for the design of clinical studies. ..
  4. T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
    Jan Storek; Fiscal Year: 2001
    ..This will give impetus for developing strategies to enable older patients to generate T cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or thymus grafting. ..
  5. T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
    Jan Storek; Fiscal Year: 2002
    ..This will give impetus for developing strategies to enable older patients to generate T cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or thymus grafting. ..
  6. Preclinical Testing of Interleukin-7 in Primates
    Jan Storek; Fiscal Year: 2002
    ..These results will be used for the design of clinical studies. ..
  7. T CELL RECONSTITUTION AFTER STEM CELL AUTOGRAFTING
    Jan Storek; Fiscal Year: 2003
    ..This will give impetus for developing strategies to enable older patients to generate T cells from hemopoietic progenitors, e.g., using thymopoietic cytokines or thymus grafting. ..
  8. Preclinical Testing of Interleukin-7 in Primates
    Jan Storek; Fiscal Year: 2003
    ..These results will be used for the design of clinical studies. ..